中央研究院生醫轉譯研究中心(BioTReC)與台灣默德納(Moderna Taiwn)11月28日於國家生技研究園區舉辦「2025默德納台灣mRNA前瞻新創獎」頒獎典禮暨獲獎計畫發表會，長聖生技的同種異體CAR-γδ T 細胞CAR001治療復發/難治型實體癌獲得評審一致的肯定，從產學研醫各界提供的重要交流平台持續創新發展與造福更多需要的病人。
On November 28th, the Biomedical Translational Research Center (BioTReC) of Academia Sinica and Moderna Taiwn Taiwan held the "2025 Moderna Taiwan mRNA Foresight Innovation Award" ceremony and award-winning project presentation at the National Biotechnology Research Park. Ever-Supreme's allogeneic CAR-γδ T cell CAR001 therapy for relapsed/refractory solid tumors received unanimous recognition from the judges. The project continues to innovate and develop, benefiting more patients in need, through an important exchange platform provided by industry, academia, research, and medicine.
